---
figid: PMC6827047__cancers-11-01618-g003
figlink: /pmc/articles/PMC6827047/figure/cancers-11-01618-f003/
number: Figure 3
caption: 'Targeted components of the MAPK and AKT signaling cascades by small-molecule
  inhibitors in cancer. Effective targeting of the pathway intermediates is an efficient
  tactic in the case of constitutively activated signaling cascades, such as the MAPK
  pathway in cancer. Successful inhibition of a step in the cascade impairs the downstream
  progression of the pathway and its overall aberrant function. Combinations of inhibitors
  or multi-targeting molecules are being investigated, as they might provide more
  efficient manipulation of the entire signaling pathway. (MAPK: mitogen-activated
  protein kinase AKT: v-akt murine thymoma viral oncogene homolog 1).'
pmcid: PMC6827047
papertitle: 'A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer.'
reftext: Cornelia Braicu, et al. Cancers (Basel). 2019 Oct;11(10):1618.
pmc_ranked_result_index: '4905'
pathway_score: 0.8190593
filename: cancers-11-01618-g003.jpg
figtitle: Targeted components of the MAPK and AKT signaling cascades by small-molecule
  inhibitors in cancer
year: '2019'
organisms: Homo sapiens
ndex: 0056f981-df27-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6827047__cancers-11-01618-g003.html
  '@type': Dataset
  description: 'Targeted components of the MAPK and AKT signaling cascades by small-molecule
    inhibitors in cancer. Effective targeting of the pathway intermediates is an efficient
    tactic in the case of constitutively activated signaling cascades, such as the
    MAPK pathway in cancer. Successful inhibition of a step in the cascade impairs
    the downstream progression of the pathway and its overall aberrant function. Combinations
    of inhibitors or multi-targeting molecules are being investigated, as they might
    provide more efficient manipulation of the entire signaling pathway. (MAPK: mitogen-activated
    protein kinase AKT: v-akt murine thymoma viral oncogene homolog 1).'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - AKT3
  - AKT1
  - AKT2
  - MTOR
  - BRAF
  - MAPK1
  - MAPK3
  - MAPK8
  - MAPK11
  - MAPK9
  - MAPK10
  - MAPK13
  - MAPK12
  - MAPK14
  - MAP2K1
  - MAP2K2
  - RPTOR
  - PDK1
  - PTEN
  - HRAS
  - KRAS
  - NRAS
  - Sorafenib
  - Vemurafenib
  - Dabrafenib
  - Silimarin
  - rapamycin
  - Cancer
  - Lung cancer
genes:
- word: AKT/MTOR
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT/MTOR
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: AKT/MTOR
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: AKT/MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: ERK1/2
  symbol: ERK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: ERK1/2
  symbol: ERK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK8
  entrez: '5599'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK9
  entrez: '5601'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK10
  entrez: '5602'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: MEK1/2
  symbol: MEK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MEK1/2
  symbol: MEK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: MTORC1
  symbol: mTORC1
  source: bioentities_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: MTORC1
  symbol: mTORC1
  source: bioentities_symbol
  hgnc_symbol: RPTOR
  entrez: '57521'
- word: PDK1
  symbol: PDK1
  source: hgnc_symbol
  hgnc_symbol: PDK1
  entrez: '5163'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
chemicals:
- word: Sorafenib
  source: MESH
  identifier: C471405
- word: Vemurafenib
  source: MESH
  identifier: C551177
- word: Dabrafenib
  source: MESH
  identifier: C561627
- word: Silimarin
  source: MESH
  identifier: D012838
- word: rapamycin
  source: MESH
  identifier: D020123
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
---
